- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01921322
Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy
Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target
Study Overview
Detailed Description
Primary objective:
To compare the length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus MDI
Secondary Objectives:
To compare glycemic variability (using CGM as reference method) with the 722 Paradigm Real-Time insulin pump versus MDI
This is a prospective, randomized (open label), multi-center study. The clinical study staff will conduct screening tests according to inclusion/exclusion criteria in order to verify the subject's eligibility for the study.
Inpatient Period A patient is admitted into hospital for treatment of diabetes
Randomization
Subjects are randomized (at a 1:1 ratio) to group A or B in the study database. A total of 80 subjects will be randomized into 2 study groups:
- Group A will wear 722 Paradigm Real-Time System (treated with 24h per day insulin infusion)
- Group B will be on MDI and wear the CGMS-Gold (treated with 4 insulin injections).
It is anticipated that the total duration for the study will be within one year from site initiation to finalization of all data entry and monitoring.
Each subject will participate in the study approximately 2 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Chinese PLA General Hospital
-
-
Jilin
-
Changchun, Jilin, China
- The Second Hospital of Jilin University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is 18 to 65 years old at time of screening
- A clinical diagnosis of type 2 diabetes > 6 months prior to the screening as determined by the Investigator,
- Treating with insulin at least one injection per day prior to participate in the study
- Glycosylated hemoglobin (A1C) > 8% at screening
- Subject needs to be hospitalized to receive treatment for glucose management according to Endocrinologists' discretion
- Subject is willing to follow protocol and underdo all study procedures
- Subject is willing and able to provide informed written consent personally or by legal proxy
Exclusion Criteria:
- Subject has known hypersensitivity to insulin or insulin infusion set
- Subject has been treated with drugs with a known effect on BG within 8 weeks before enrollment other than diabetes medications such as insulin or oral agents.
- random blood glucose is above 33 mmol/L
- Subject is currently using real time CGM therapy prior to screening
- Subject is currently using insulin pump therapy prior to screening
- Female subject who is pregnant, or plans to become pregnant during the course of the study
- Patients who are critically ill that must go to intensive critical care unit per Investigator discretion
Subject has any systemic disease or medical condition found on the screening tests that may interfere with the safety of the patient and efficacy of the study treatment, in the opinion of the Investigator, may preclude him/her from participating in the study. The following includes, but not limited to, those conditions:
- Female subject has a positive serum pregnancy screening test
- Subject has visually impaired or disability limits the use of RT-CGM.
- Subject has any unresolved adverse skin condition in the area of sensor placement or device replacement (e.g., psoriasis, rash, Staphylococcus infection)
- Subject has disease with a known effect on BG such as Active Graves' disease
- Subject has a history of alcohol abuse
- Any other condition, which may not be suitable for the study at physician's discretion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pump
Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
|
722 Paradigm Real-Time System
|
Active Comparator: MDI
Multiple daily insulin injections used for treatment
|
Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Target
Time Frame: Up to 14 days in hospital
|
length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus Multiple Daily Injection
|
Up to 14 days in hospital
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic Variability
Time Frame: Up to 14 days in hospital
|
Glycemic variability (mean amplitude glycemic excursion) using CGM as reference method
|
Up to 14 days in hospital
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP270
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Pump
-
University of California, San FranciscoOregon Health and Science UniversityCompletedBrain Death | Organ Donation | Delayed Graft Function | Organ Transplant Failure or RejectionUnited States
-
St. Petersburg State Pavlov Medical UniversityRecruitingIschemic Heart Disease | Coronary Artery Bypass GraftingRussian Federation
-
The University of Texas Health Science Center,...TerminatedHeart Failure | LVADUnited States
-
Wendell ScottJohnson & Johnson Surgical Vision, Inc.CompletedCataract SenileUnited States
-
Hillel Yaffe Medical CenterUnknownRight Heart Failure | Cor PulmonaleIsrael
-
Bozok UniversityCompletedMyocardial Infarction | Oxidative Stress | Cerebral OxygenationTurkey
-
University College, LondonNorthwell Health; Capital Medical University; Scientific Center of ChildrenUnknownVolume of Breast Milk Expressed Using Single Electric Breast Pumps. | Duration of Exclusive Breast-feeding | Duration of Any Breast-feedingUnited Kingdom
-
Assiut UniversityRecruitingCAD - Coronary Artery DiseaseEgypt
-
Moens MaartenCompleted